BrYet US, Inc.
- Biotech or pharma, therapeutic R&D
New metastatic cancer targeting based on physics of mass transport; first CTA Q2 2025; outstanding efficacy published Nature/Science journals; platform + pipeline; well funded; $100 M+ science grants UWashington Houston Methodist MDAnderson UC Berkeley. Focused on metastasis to lung and liver of cancer of any origin.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}